|
US2017035838A1
|
|
Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
|
|
RU2707885C2
|
|
CHLORIDE SALT OF PEPTIDE TAT-NR2B9c COMPOSITION, BASED THEREON AND METHODS FOR PRODUCTION THEREOF
|
|
WO2015181757A1
|
|
Lyophilized formulation of tat-nr2b9c with acetylation scavenger
|
|
AU2013352437A1
|
|
Lyophilized formulation of TAT-NR2B9c
|
|
ZA201302811B
|
|
Nd2 peptides and methods of treating neurological disease
|
|
US2013156704A1
|
|
Therapy for subarachnoid hemorrhage and ischemia
|
|
MX2014007031A
|
|
THERAPY FOR SUBARACHNOID HEMORRHAGE and ISCHEMIA.
|
|
KR20190107195A
|
|
Combination therapy with psd-95 inhibitor for ischemia
|
|
WO2012174488A2
|
|
Agents and methods for treating ischemic and other diseases
|
|
CA2762338A1
|
|
Therapy for subarachnoid hemorrhage and ischemia
|
|
MX2013003330A
|
|
Nd2 peptides and methods of treating neurological disease.
|
|
EP2616094A2
|
|
Treatment of penetrative injury to the brain
|
|
WO2011072275A2
|
|
Agents and methods for treating ischemic and other diseases
|
|
BRPI1010718A2
|
|
model systems and treatment regimens to treat neurological disease.
|
|
CN102088990A
|
|
Treatment for epilepsy
|
|
AU2008223469A1
|
|
Treating stroke and other diseases without inhibiting N-type calcium channels
|
|
CA2510056A1
|
|
Treatment of injury in mammalian cells
|
|
EP1709084A1
|
|
Polypeptides for modulating binding of trp channel proteins and trp-associated proteins
|
|
US7510824B2
|
|
Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
|
